Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06003387 |
| Consolidated Lead Sponsor | CSL Behring |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 35 participants (ESTIMATED) |
| Registered Start Date | 2024-01-30 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UC San Diego Health and Moores Cancer Center | San Diego, CA | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
| The University of Texas Health Science Center at Houston | Houston, TX | Open Hospital Dossier -> |
| Royal Prince Alfred Hospital | Camperdown, Australia | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.